ES2582556T3 - Derivados de imidazo-oxadiazol e imidazo-tiadiazol - Google Patents

Derivados de imidazo-oxadiazol e imidazo-tiadiazol Download PDF

Info

Publication number
ES2582556T3
ES2582556T3 ES13724172.5T ES13724172T ES2582556T3 ES 2582556 T3 ES2582556 T3 ES 2582556T3 ES 13724172 T ES13724172 T ES 13724172T ES 2582556 T3 ES2582556 T3 ES 2582556T3
Authority
ES
Spain
Prior art keywords
methyl
mmol
nmr
imidazo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13724172.5T
Other languages
English (en)
Spanish (es)
Inventor
Anna Quattropani
Dominique Swinnen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Application granted granted Critical
Publication of ES2582556T3 publication Critical patent/ES2582556T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES13724172.5T 2012-06-05 2013-05-23 Derivados de imidazo-oxadiazol e imidazo-tiadiazol Active ES2582556T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261655544P 2012-06-05 2012-06-05
EP12170840.8A EP2671885A1 (en) 2012-06-05 2012-06-05 Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
US201261655544P 2012-06-05
EP12170840 2012-06-05
PCT/EP2013/001521 WO2013182274A1 (en) 2012-06-05 2013-05-23 Imidazo-oxadiazole and imidazo-thiadiazole derivatives

Publications (1)

Publication Number Publication Date
ES2582556T3 true ES2582556T3 (es) 2016-09-13

Family

ID=46320789

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13724172.5T Active ES2582556T3 (es) 2012-06-05 2013-05-23 Derivados de imidazo-oxadiazol e imidazo-tiadiazol

Country Status (9)

Country Link
US (2) US9932354B2 (OSRAM)
EP (2) EP2671885A1 (OSRAM)
JP (1) JP6167465B2 (OSRAM)
CN (1) CN104395324B (OSRAM)
AU (1) AU2013270979B2 (OSRAM)
CA (1) CA2875628C (OSRAM)
ES (1) ES2582556T3 (OSRAM)
IL (1) IL236076B (OSRAM)
WO (1) WO2013182274A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
US11247987B2 (en) 2017-10-06 2022-02-15 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2160365A1 (en) * 1993-04-26 1994-11-10 Gilbert Henri Camiel Clincke Use of sabeluzole in chronic neurodegenerative diseases
CN100415744C (zh) * 2001-02-20 2008-09-03 阿斯特拉曾尼卡有限公司 用于治疗与gsk3有关的病症的2-芳基氨基-嘧啶
EP1399440B1 (en) * 2001-06-15 2009-06-03 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
US20050154202A1 (en) * 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
ATE339419T1 (de) * 2002-08-02 2006-10-15 Vertex Pharma Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
EP2388263A1 (en) * 2005-08-04 2011-11-23 Sirtris Pharmaceuticals, Inc. Imidazo[2,1-b]thiazole derivatives as sirtuin modulators
DK2193133T3 (en) * 2007-09-27 2015-10-05 Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS
EP2307425B1 (en) * 2008-07-29 2014-03-26 Merck Patent GmbH Imidazothiadiazoles derivatives
JP5667058B2 (ja) * 2008-09-23 2015-02-12 ウィスタ ラボラトリーズ リミテッド 凝集したタウ分子に対するリガンド

Also Published As

Publication number Publication date
CA2875628C (en) 2021-01-19
EP2671885A1 (en) 2013-12-11
US20150175628A1 (en) 2015-06-25
CN104395324B (zh) 2017-09-12
JP2015522556A (ja) 2015-08-06
JP6167465B2 (ja) 2017-07-26
CA2875628A1 (en) 2013-12-12
IL236076A0 (en) 2015-02-01
US10696690B2 (en) 2020-06-30
EP2855488A1 (en) 2015-04-08
IL236076B (en) 2019-05-30
AU2013270979A1 (en) 2015-01-22
US20180215770A1 (en) 2018-08-02
AU2013270979B2 (en) 2017-04-27
CN104395324A (zh) 2015-03-04
EP2855488B1 (en) 2016-04-13
WO2013182274A1 (en) 2013-12-12
US9932354B2 (en) 2018-04-03

Similar Documents

Publication Publication Date Title
AU2020203464B2 (en) Sulfonylureas and related compounds and use of same
JP5524171B2 (ja) キナーゼ阻害剤
JP7163385B2 (ja) ジアザスピロｒｏｃｋ阻害剤
ES2945314T3 (es) Derivados de benzoimidazol como inhibidores de PAD4
ES2542764T3 (es) N-((6-amino-piridin-3-il)metil)-heteroaril-carboxamidas como inhibidores de la calicreína plasmática
ES2855135T3 (es) Amidas heterocíclicas como inhibidores de quinasa
ES2635016T3 (es) Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas
RU2610840C2 (ru) Тиазолопиримидины
KR20080087070A (ko) 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제
JP7369458B2 (ja) ヒストンデアセチラーゼ６阻害剤としての１，２，４－オキサジアゾール誘導体
ES2520647T3 (es) Compuestos de triazolopiridina
KR20090121399A (ko) 화합물
AU2006332694A1 (en) Substituted bis-amide metalloprotease inhibitors
KR20090122300A (ko) 화합물
KR20150108372A (ko) 단백질 키나아제의 억제제로서의 아자인돌 유도체
ES2934986T3 (es) Derivados heterocíclicos
CA3106513A1 (en) Heteroaromatic compounds as vanin inhibitors
ES2582556T3 (es) Derivados de imidazo-oxadiazol e imidazo-tiadiazol
CA3120037A1 (en) Heteroaromatic compounds as vanin inhibitors
ES3009813T3 (en) Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
JP6229717B2 (ja) ガンマセクレターゼモジュレーターとしての縮合トリアゾール誘導体
CN104364258A (zh) 用于治疗神经变性疾病的螺四氢-苯并噻吩衍生物
JP2012532126A (ja) フラビン誘導体
JP2008510734A (ja) キナーゼ阻害剤
WO2024158872A1 (en) 1,3-indole-propanamide inhibitors of sars-cov-2 plpro/nsp3 and derivatives thereof